Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 34Recruiting 12Completed 3Terminated 2Suspended 2Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Xeroderma Pigmentosum 1Turcot syndrome 1Neuroblastoma 1Lymphoma 1Hematologic Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 5Radiotherapy 4Radiation 4ALT-803 4fludarabine 3Specimen Handling 3Prednisone 3Nivolumab 3Etoposide 3Cytarabine 3Cyclophosphamide 3Cisplatin 3sacituzumab govitecan 2daratumumab 2atezolizumab 2Vincristine 2Temozolomide 2Surveys and Questionnaires 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Irinotecan 2Gemcitabine 2Doxorubicin 2Biopsy 2Bevacizumab 2Androgen Antagonists 2130-nm albumin-bound paclitaxel 2zimberelimab 1vocimagene amiretrorepvec 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × CTLA-4 Antigen × 90 days × Clear all
NCT04500548 2026-06-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡